Nucleic Acid–Based Drug Products
Transform your nucleic acid therapeutics (NAT) from complex molecules into stable, high-performing drug products. Coriolis Pharma offers specialized development services across all major modalities—including mRNA-LNPs, oligonucleotides (ASO, siRNA), and CRISPR systems.
By integrating deep formulation expertise with phase-appropriate analytical characterization, we overcome stability challenges and deliver optimized liquid or lyophilized solutions tailored to your molecule’s unique needs. Partner with us to ensure your nucleic acid therapeutic remains potent and effective throughout its entire lifecycle.
Specialized Nucleic Acid Services and Capabilities
Each nucleic acid modality brings its own scientific challenges, and Coriolis provides the tailored strategies needed to address them. With strong scientific dedication, profound know-how across nucleic acid based modalities, and high‑quality analytical and formulation capabilities, we help clients overcome critical development challenges and bring innovative nucleic acid products forward with confidence.
Nucleic Acid Secondary Structure
At Coriolis Pharma, we support successful drug product development with robust and sensitive analytical methods to ensure the stability and effectiveness of your drug products. Coriolis Pharma experts use advanced techniques such as CD, FTIR and DSC to assess nucleic acid structures.
Characterization of Nanoparticulate Delivery Systems
Efficient transport and protection of nucleic acid payloads depend on advanced delivery systems like Lipid Nanoparticles (LNPs) and polymer-based platforms. Coriolis Pharma provides industry-leading expertise in the characterization of nanoparticulate delivery systems, ensuring a profound understanding of particle properties and long-term stability.
Our analytical suite spans six orders of magnitude from nanometer-scale free nucleotides to (sub)visible particles. We deliver the precise data and analytical depth required to build robust CMC packages, supporting your product from early development through to regulatory approval.
Viral Vectors as Delivery Systems for Nucleic Acid Therapeutics
Viral vectors, including AAVs and Lentiviruses (LV), are essential for precise genetic payload delivery. Coriolis Pharma ensures these complex platforms maintain peak infectivity and stability while safeguarding critical quality attributes (CQAs).
Our experts provide tailored R&D and CMC aligned analytical packages to navigate the challenges of immunogenicity and toxicity. Coriolis Pharma help you transition from innovation to clinical success with robust data and optimized formulation strategies.
Particle Identification
Accurate identification and source attribution of particulate matter in biopharmaceutical drug products are essential for effective troubleshooting and comprehensive root cause analysis.
Given the potential impact on product quality, patient safety, and regulatory compliance, rapid analytical turnaround is often critical.
Upon request, Coriolis experts provide accelerated, fast-track analytical services, enabling detailed characterization of particulate contaminants within a matter of days.
Advanced Lyophilization Expertise
Transitioning sensitive mRNA-LNPs from ultra-cold storage (< -70°C) to stable 2-8 °C liquid or lyophilized products provides a significant commercial edge.
Coriolis Pharma offers expert lyophilization services for mRNA, oligonucleotides, and AOCs. Using a model-based approach, we optimize freeze-drying cycles and scale-relevant processes to ensure long-term stability. From bulk drug substance to final drug product, we streamline your path to GMP production with robust, scalable manufacturing solutions.
Nanoparticle Composition & non-GMP Manufacturing
Coriolis Pharma accelerates the journey to the clinic with specialized process development for LNPs and other nucleic acid delivery systems. Our experts optimize the clinical production using your specific lipids and excipients to ensure consistent, stable, and well-characterized nanoparticles.
From scale-relevant non GMP manufacturing to final drug product formulation, our data driven approach guarantees a seamless transition to GMP clinical production. Maximize your flexibility and product quality with processes built for scalability and regulatory success.
Nucleic Acid Resources
Publications
Drug Product Development of Lipid Nanoparticle-Based mRNA Therapeutics and Vaccines
April 9, 2026
Comprehensive Biotherapeutic Expertise
Our deep-rooted academic background, drug development and commercialization expertise keep us at the cutting edge of formulation science and analytical method development. This expertise enables us to support a wide range of modalities.
Nucleic Acid Therapeutics Development Services
Coriolis Pharma’s deep expertise in formulation science and experience with a variety of nucleic acid–based therapeutic drug products equip us to support the entire product lifecycle.
Talk to Our Experts or Request a Quote
Our expert team is ready to answer your questions and guide you to the services best suited to your program’s modality, stage and challenge. If your needs are well-defined, we’ll begin the quotation process.
Nucleic Acid FAQs
-
Nucleic acids are biomolecules essential for all forms of life. They include DNA and RNA, which carry genetic information crucial for the development, functioning and reproduction of all living organisms. Nucleic acid–based drug products are a promising therapeutic modality that can address challenging medical needs by achieving long-lasting or curative effects through gene expression, inhibition, addition, replacement or editing. These drugs range from a few base pairs (oligonucleotides) to several hundred base pairs (nucleic acid macromolecules).
-
Coriolis offers science-driven services to assess and enhance the stability and cellular uptake of nucleic acid–based drug products. We develop liquid and lyophilized formulations and employ sensitive and orthogonal analytical techniques for comprehensive product characterization. This includes ensuring the conformational stability of nucleic acids through techniques like circular dichroism (CD).
-
We utilize state-of-the-art methods like circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) to assess the conformational structure of nucleic acids, ensuring their stability and effectiveness. Our comprehensive particle characterization methods also play a crucial role in this process.
-
To master the complexity of LNP and polymer platforms, we apply a multi-modal analytical strategy spanning six orders of magnitude. By integrating core techniques like DLS and NTA with advanced subvisible imaging and analytical ultracentrifugation (AUC), we precisely differentiate between free nucleic acids, intact particles, and aggregates. This high-resolution characterization is essential for optimizing formulation stability and ensuring consistent therapeutic performance at every stage of development.
-
Coriolis bridges the gap between nanoparticle concepts and scalable drug products by integrating formulation design with process development in parallel. By optimizing nanoparticle composition alongside robust, scale-relevant manufacturing processes, we ensure consistent quality and stability for human application. This drug-product-centered approach streamlines the transition from non-GMP development to GMP production, ensuring a more efficient and predictable path to clinical manufacturing.
INFOGRAPHIC
Driving Success from Preclinical to Commercial Approval & Beyond
A guide for early and late-stage development, commercialization, and lifecycle management
Learn More
